Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890720594> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2890720594 abstract "e16063 Background: Pazopanibhas been approved for treatment of patients (pts) with mRCC based on the prospective randomized trial that enrolled only pts with adequate renal parameters. There are no data on the toxicity profile and efficacy of pazopanib in pts with renal insufficiency (RI).The aim of this study is to investigate the effect of renal function on treatment outcomes in pts treated with pazopanib for mRCC. Methods: We retrospectively analyzed the data of the mRCC pts treated with pazopanib with respect to renal function in eleven Italian institutions from January 2010 to June 2016. Baseline glomerular filtration rate (GFR) was calculated using the Modification of Diet in Renal Disease (MDRD) formula at the time of therapy initiation. Pts with MDRD < 60 mL/min/1.73 m 2 (group 1) were compared with pts with MDRD ≥60 mL/min/1.73 m 2 (group 2) in terms of response rates, progression free survival (PFS), overall survival (OS) and side effects. Results: One hundred and twenty-ninepts with mRCC were included in this study: 70 pts in group 1 and 59 pts in group 2. 67% of pts were male, median age was 66 years (34-83) and median CrCl was 49 ml/min (6.3-59.5) in group 1. In group 2, 64% of pts were male, median age was 65 years (38-80), and median CrCl was 64 ml/min (58.1-137.1) Pts with MDRD < 60 were more likely to have had a previous nephrectomy (84.3% vs 79.7%). No difference between the 2 groups was observed in terms of outcomes: PFS was 9.6 months (0.6–56.9) and 9.0 months (0.4–60.1), OS was 16.1 months (1.3–56.9) and 17.0 months (1.2–60.1), for MDRD < 60 group and MDRD ≥60 respectively. The disease control rate was 85.8% in group 1, and 72.9% in group 2. About grade 1-2 toxicity, no difference between the 2 groups was reported (67.1% vs 67.8%) while a higher incidence of grade 3-4 toxicity was evident in the group 1 (25.7% vs 18.6%). Conclusions: RI was commonly observed in pts with mRCC. Renal function at therapy initiation does not adversely affect the efficacy and safety of pazopanib. More frequent monitoring of side-effects in patients with RI is recommended." @default.
- W2890720594 created "2018-09-27" @default.
- W2890720594 creator A5008661123 @default.
- W2890720594 creator A5013338705 @default.
- W2890720594 creator A5013913173 @default.
- W2890720594 creator A5030345469 @default.
- W2890720594 creator A5038198711 @default.
- W2890720594 creator A5047133719 @default.
- W2890720594 creator A5049661977 @default.
- W2890720594 creator A5056348833 @default.
- W2890720594 creator A5057926104 @default.
- W2890720594 creator A5063457914 @default.
- W2890720594 creator A5065945024 @default.
- W2890720594 creator A5071060598 @default.
- W2890720594 creator A5071208029 @default.
- W2890720594 creator A5074987624 @default.
- W2890720594 date "2017-05-20" @default.
- W2890720594 modified "2023-09-26" @default.
- W2890720594 title "The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study." @default.
- W2890720594 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e16063" @default.
- W2890720594 hasPublicationYear "2017" @default.
- W2890720594 type Work @default.
- W2890720594 sameAs 2890720594 @default.
- W2890720594 citedByCount "0" @default.
- W2890720594 crossrefType "journal-article" @default.
- W2890720594 hasAuthorship W2890720594A5008661123 @default.
- W2890720594 hasAuthorship W2890720594A5013338705 @default.
- W2890720594 hasAuthorship W2890720594A5013913173 @default.
- W2890720594 hasAuthorship W2890720594A5030345469 @default.
- W2890720594 hasAuthorship W2890720594A5038198711 @default.
- W2890720594 hasAuthorship W2890720594A5047133719 @default.
- W2890720594 hasAuthorship W2890720594A5049661977 @default.
- W2890720594 hasAuthorship W2890720594A5056348833 @default.
- W2890720594 hasAuthorship W2890720594A5057926104 @default.
- W2890720594 hasAuthorship W2890720594A5063457914 @default.
- W2890720594 hasAuthorship W2890720594A5065945024 @default.
- W2890720594 hasAuthorship W2890720594A5071060598 @default.
- W2890720594 hasAuthorship W2890720594A5071208029 @default.
- W2890720594 hasAuthorship W2890720594A5074987624 @default.
- W2890720594 hasConcept C126322002 @default.
- W2890720594 hasConcept C126894567 @default.
- W2890720594 hasConcept C143998085 @default.
- W2890720594 hasConcept C159641895 @default.
- W2890720594 hasConcept C2777472916 @default.
- W2890720594 hasConcept C2778439243 @default.
- W2890720594 hasConcept C2779490328 @default.
- W2890720594 hasConcept C2780091579 @default.
- W2890720594 hasConcept C2781068499 @default.
- W2890720594 hasConcept C71924100 @default.
- W2890720594 hasConceptScore W2890720594C126322002 @default.
- W2890720594 hasConceptScore W2890720594C126894567 @default.
- W2890720594 hasConceptScore W2890720594C143998085 @default.
- W2890720594 hasConceptScore W2890720594C159641895 @default.
- W2890720594 hasConceptScore W2890720594C2777472916 @default.
- W2890720594 hasConceptScore W2890720594C2778439243 @default.
- W2890720594 hasConceptScore W2890720594C2779490328 @default.
- W2890720594 hasConceptScore W2890720594C2780091579 @default.
- W2890720594 hasConceptScore W2890720594C2781068499 @default.
- W2890720594 hasConceptScore W2890720594C71924100 @default.
- W2890720594 hasLocation W28907205941 @default.
- W2890720594 hasOpenAccess W2890720594 @default.
- W2890720594 hasPrimaryLocation W28907205941 @default.
- W2890720594 hasRelatedWork W2067663694 @default.
- W2890720594 hasRelatedWork W2227116226 @default.
- W2890720594 hasRelatedWork W2233471907 @default.
- W2890720594 hasRelatedWork W2242011905 @default.
- W2890720594 hasRelatedWork W2586600986 @default.
- W2890720594 hasRelatedWork W2589184112 @default.
- W2890720594 hasRelatedWork W2590871439 @default.
- W2890720594 hasRelatedWork W2591165238 @default.
- W2890720594 hasRelatedWork W2604171410 @default.
- W2890720594 hasRelatedWork W2606055055 @default.
- W2890720594 hasRelatedWork W2617974212 @default.
- W2890720594 hasRelatedWork W2782110733 @default.
- W2890720594 hasRelatedWork W2785103248 @default.
- W2890720594 hasRelatedWork W2789662395 @default.
- W2890720594 hasRelatedWork W2890521087 @default.
- W2890720594 hasRelatedWork W2891573627 @default.
- W2890720594 hasRelatedWork W2921350985 @default.
- W2890720594 hasRelatedWork W2955631801 @default.
- W2890720594 hasRelatedWork W2964700594 @default.
- W2890720594 hasRelatedWork W3029127361 @default.
- W2890720594 isParatext "false" @default.
- W2890720594 isRetracted "false" @default.
- W2890720594 magId "2890720594" @default.
- W2890720594 workType "article" @default.